Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | October 24, 2013 |
| Target | Optimer Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Cubist Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 801M USD |
| Advisor(s) | J.P. Morgan Securities Centerview Partners (Financial) Sullivan & Cromwell (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 900 |
| Revenue | 1.1B USD (2013) |
Cubist Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the research, commercialization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.
| Deal Context for Buyer | # |
|---|---|
| Overall | 5 of 5 |
| Sector: Life Science | 5 of 5 |
| Type: Add-on Acquisition | 5 of 5 |
| State: New Jersey | 1 of 1 |
| Country: United States | 5 of 5 |
| Year: 2013 | 2 of 2 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-07-30 |
Trius Therapeutics
San Diego, California, United States Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). |
Buy | $707M |
